Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cambium BioASX:CMB 32 EV-to-EBITDA is -3.00 as of Jul. 15, 2026. GuruFocus rates ASX:CMB with a GF Score™ of 32/100. The stock has 4 warning signs investors should review. Among 398 Biotechnology companies, Cambium Bio ranks worse than 251256.03% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Cambium Bio's enterprise value is A$10.71 Mil.
Cambium Bio's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was A$-3.57 Mil. Therefore, Cambium Bio's EV-to-EBITDA for today is -3.00.
The historical rank and industry rank for Cambium Bio's EV-to-EBITDA or its related term are showing as below:
ASX:CMB'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -3 Med: 0 Max: 0
Current: -3
ASX:CMB's EV-to-EBITDA is ranked worse than 100% of 398
companies
in the Biotechnology industry
Industry Median: 12.62
vs ASX:CMB: -3.00
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Cambium Bio (ASX:CMB) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cambium Bio's PE Ratio (TTM) for today is calculated as:
Cambium Bio's share price for today is A$0.405.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cambium Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.186.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Cambium Bio's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:CMB vs VRTX, REGN, ALNY: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Cambium Bio's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cambium Bio EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cambium Bio's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Cambium Bio's EV-to-EBITDA falls into.
Cambium Bio's current Enterprise Value is A$10.71 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cambium Bio's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was A$-3.57 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cambium Bio (ASX:CMB) has a EV-to-EBITDA of -3.00 as of Jul. 15, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Cambium Bio. According to the industry distribution chart, Cambium Bio ranks #999999 out of 398 companies in the Biotechnology industry.
Is Cambium Bio's EV-to-EBITDA too high?
Cambium Bio's current EV-to-EBITDA is -3.00. Based on the distribution chart, Cambium Bio ranks #999999 out of 398 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Cambium Bio has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Cambium Bio's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cambium Bio ranks #999999 out of 398 companies for EV-to-EBITDA. This places Cambium Bio in the lower half of its industry. The industry median EV-to-EBITDA is 12.62. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 12.62, based on 398 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Cambium Bio. For the Biotechnology industry, the median EV-to-EBITDA is 12.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cambium Bio's current EV-to-EBITDA is -3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cambium Bio stock overvalued right now?
Cambium Bio (ASX:CMB) has a current EV-to-EBITDA of -3.00. The current EV-to-EBITDA is -3.00. Cambium Bio's overall GF Score™ is 32/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Cambium Bio (ASX:CMB), the current EV-to-EBITDA is -3.00 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cambium Bio Ltd is a clinical-stage regenerative medicine company in Australia. It focuses on the development of biologics for ophthalmology and tissue repair applications. Its technology platform is based on human platelet lysate, which is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. The company's product candidate, Elate Ocular, is being developed to address unmet medical needs in the treatment of dry eye disease. In addition, its stem cell platform, Progenza, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications.
32GF Score
Get the complete analysis for ASX:CMB
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CMB has been successfully added to your 
